Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Receivables (2023 - 2025)

Bioregenx (BRGX) has 3 years of Receivables data on record, last reported at $62610.0 in Q3 2025.

  • For Q3 2025, Receivables rose 222.03% year-over-year to $62610.0; the TTM value through Sep 2025 reached $62610.0, up 222.03%, while the annual FY2024 figure was $203992.0, 95.06% up from the prior year.
  • Receivables reached $62610.0 in Q3 2025 per BRGX's latest filing, up from $21115.0 in the prior quarter.
  • Across five years, Receivables topped out at $203992.0 in Q4 2024 and bottomed at $10943.0 in Q2 2024.
  • Average Receivables over 3 years is $55626.6, with a median of $20278.5 recorded in 2024.
  • The widest YoY moves for Receivables: up 222.03% in 2025, down 0.18% in 2025.
  • A 3-year view of Receivables shows it stood at $104581.0 in 2023, then soared by 95.06% to $203992.0 in 2024, then plummeted by 69.31% to $62610.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $62610.0 in Q3 2025, $21115.0 in Q2 2025, and $11155.0 in Q1 2025.